Lila Vance arrived at Tranquil Gardens at 10:15 AM, driving a twelve-year-old sedan with a dent in the rear quarter panel that she had never bothered to repair. She was sixty-eight years old, five feet four inches tall, with steel-gray hair cut short and the kind of posture that suggested a spine made of rebar. During her thirty-two years with the Federal Bureau of Inquiry, she had investigated forty-seven homicides, testified in sixty-one trials, and earned a reputation for closing the cases that no one else wanted. Her last case, the Meridian River Strangler, had ended with a conviction and her own retirement. She had not missed the Bureau. She missed the clarity.
Silas met her in the lobby, a cavernous space decorated in soothing beige and pastel watercolors of pastoral landscapes. The receptionist, a young woman with elaborate acrylic nails, did not look up from her phone as Lila signed in under a false name: Margaret Cole.
"Your room?" Lila said.
"Follow me."
Room 104 was exactly as Silas had left it: orderly, sparse, smelling faintly of old paper and rubbing alcohol. Lila surveyed the space with a single sweeping glance, an old habit, cataloguing exits and anomalies. She sat in the only chair, a vinyl armchair beside the window, leaving Silas to sit on the edge of his bed.
"Show me," she said.
Silas handed her the blue notebook. She read it slowly, turning the pages with the care of someone who understood that information was physical evidence. When she reached the final page—the diagram with its red-ink arrows and the question *What if they are instructions?*—she stopped. Her expression did not change, but her breathing slowed.
"Let me be clear," she said, closing the notebook and placing it on the bedside table. "You are alleging that OmniCure Biotech is using its AI monitoring system to deliberately induce fatal cardiac events in elderly patients enrolled in its clinical trials. That the deaths are designed to appear natural, and that the motive is... what, exactly? Covering up drug side effects? Reducing the cost of long-term care? Proving the system's predictive accuracy by manufacturing the outcomes?"
"I don't know yet," Silas admitted. "The motive is secondary to the mechanism. Once we understand the mechanism, the motive will reveal itself. That is the nature of logic."
Lila leaned back in the vinyl chair, which creaked under her. "The Bureau will laugh you out of the building, Silas. I could have told you that even when I had a badge. Now I'm just a retiree with a pension and a bad knee. What makes you think I can help?"
"Because you understand something that most of your former colleagues do not," Silas said. "Crime evolves faster than the law. The first poisoner was probably believed to be a wizard. The first hacker was treated as a prankster. The gap between criminal innovation and investigative methodology is where murderers hide. Right now, inside this building, a machine is killing people, and there is no statute in the Meridian Criminal Code that even acknowledges that possibility. I need someone who can bridge that gap."
Lila was silent for a long moment. Outside the window, a groundskeeping crew trimmed hedges into geometric shapes.
"Five deaths," she said finally. "All in this facility?"
"All here. All OmniCure trial participants. All flagged as low-risk within forty-eight hours of death. All died of sudden cardiac failure between the hours of midnight and 8:00 AM, when staffing is minimal and response times are slowest."
"Who else knows?"
"Dr. Lena Cordova, the medical director. She has dismissed each death as natural. The families were informed of pre-existing conditions. No autopsies were conducted. The state medical examiner has no open investigations. The FDA has received no adverse event reports related to Aegis-7—I checked."
Lila rubbed her knee absently. "Show me the terminal."
They walked together to Room 217, now empty and stripped of its bedding. The VitalSync terminal was still mounted on the wall, its screen dark. Silas pressed the power button. Nothing happened.
"They disconnected it," he said. "Last night it was operational. I photographed it."
Lila examined the mounting bracket. "When did the patient die?"
"Yesterday morning. 07:42 AM."
"Standard protocol for medical equipment after a death?"
"I asked the head nurse this morning," Silas said. "She told me that OmniCure's policy is to remotely decommission all devices within twenty-four hours of a patient's expiration. The data is uploaded to their cloud servers and the local terminal is wiped."
"So the evidence is gone."
"The local evidence is gone. The remote evidence is on OmniCure's servers, in the city of Asterion. Protected by proprietary encryption, corporate attorneys, and a legal system that considers data privacy a higher priority than criminal discovery."
They walked back to the common room, where a television played a morning news program. The lead story concerned a congressional debate over the Algorithmic Governance Act, a bill that would require transparency in automated decision-making systems used by federal agencies. The bill's sponsor, Senator Eleanor Cross of the Northern Marches, was shown at a podium, saying: "If a machine makes a decision that affects a citizen's life, that citizen has a right to know how the decision was made. The black box is not compatible with democracy."
Lila watched the segment with narrowed eyes. "Senator Cross has been pushing that bill for two years. It has never made it out of committee. OmniCure is one of the largest donors to the Health Innovation PAC, which happens to fund the campaigns of several key committee members."
"Are you suggesting corruption?" Silas asked.
"I am suggesting that power flows toward power," Lila said. "I spent three decades learning that lesson. The question is not whether powerful people protect powerful companies. The question is how far they will go."
That afternoon, Lila made a series of telephone calls from the payphone in the library lobby, using a prepaid calling card purchased with cash. The first call was to a former colleague in the FBI's cybercrime division, a man named Arthur Cho who had once owed her a favor. She asked him to run a background check on OmniCure Biotech and its CEO, Marcus Voss. The second call was to a journalist at the Carpathia Sentinel, asking for archived articles about nursing home deaths. The third was to the state medical examiner's office, where she left a message requesting a meeting regarding "irregularities in geriatric mortality statistics."
By evening, Arthur Cho had called back. His voice was low, cautious. "Lila, what are you into?"
"Tell me about OmniCure."
A pause, the sound of keys clicking. "The company is clean. Too clean. No regulatory actions, no lawsuits, no whistleblower complaints that survived initial review. They have government contracts with the Department of Veterans' Affairs and three state health departments. Their board includes a former FDA commissioner and a retired federal judge."
"And Marcus Voss?"
"PhD in computational biology from Carpathia Tech. Worked at GenSolve Pharmaceuticals for twelve years, rose to vice president of research. Left under what the press release called a strategic realignment. Reading between the lines, I'd say he was pushed. GenSolve filed a sealed complaint against him for intellectual property theft, but it was settled out of court. Two years later, he founded OmniCure with venture capital funding from Asterion Equity Partners."
"Any criminal record?"
"Not even a parking ticket. Lila, why are you asking about this?"
"Research," she said. "One more thing. Can you pull the FDA adverse event database for a clinical trial called Aegis-7?"
More typing. "Aegis-7. Phase III trial for an anticoagulant called Praxaven. Sponsor is OmniCure. Enrollment of approximately 2,400 patients across twelve sites in Meridia. Status: ongoing. Adverse events reported: zero. Wait, that can't be right. No drug in Phase III has zero adverse events. Even aspirin causes stomach bleeding."
"Is that publicly available?"
"It should be. But the database shows zero. Maybe they haven't uploaded yet. Or maybe someone hasn't wanted to look."
Lila thanked him and hung up. She found Silas in the periodicals section, reading a financial newspaper from the previous month. He looked up as she approached.
"Zero adverse events," she said. "Across 2,400 patients in twelve facilities. That is statistically impossible."
Silas closed the newspaper. "Unless the adverse events are being classified as something else. Or unless the patients who experience them are no longer alive to report them, and their deaths are attributed to pre-existing conditions."
"We need to find another facility," Lila said. "Another site in the Aegis-7 trial. If the same pattern exists elsewhere, then this is not an isolated incident. It is a systematic program."
That night, after Lila had checked into a motel three miles away, Silas sat alone in his room and reviewed his notes. He had begun compiling a list of all twelve Aegis-7 trial sites from the clinicaltrials.gov registry. Six were in Meridia. The remaining six were in the neighboring Federated States of Albion, beyond Meridian jurisdiction. He cross-referenced the addresses with obituary databases, searching for clusters of cardiac deaths among elderly patients. By midnight, he had found three more facilities with elevated mortality rates among trial participants. The pattern was unmistakable.
He was about to call Lila when his door opened.
Dr. Lena Cordova stood in the doorway, her tablet tucked under one arm. Her expression was no longer efficient and dismissive. It was cold.
"Professor Crane," she said. "I need you to come with me. There has been a development."
Silas did not move. "What kind of development?"
"Another patient has been flagged by VitalSync. A high-risk alert, not low-risk. A woman in Room 309, Mrs. Eleanor Vance. The system predicts she will experience a cardiac event within the next twelve hours. I thought you might want to observe."
The name struck Silas like a physical blow. Eleanor Vance. The similarity to Lila was unsettling. He stood slowly, slipping his notebook into his jacket pocket.
"Lead the way," he said.
They walked to Room 309, a mirror image of Harold Finch's room. An elderly woman lay in the bed, her breathing shallow, her eyes closed. Beside her, the VitalSync terminal glowed with a red alert banner: HIGH RISK. TIME TO EVENT: 11H 47M.
"Mrs. Vance has a history of congestive heart failure," Dr. Cordova said, her voice unnervingly calm. "She was enrolled in the trial six weeks ago. Until tonight, her risk profile was low. Then, suddenly, it spiked."
"What changed?"
"Nothing. That is the nature of predictive algorithms. They detect patterns that human clinicians miss. This is why VitalSync is so valuable. It sees the future before we do."
Silas stared at the countdown timer on the screen. Eleven hours and forty-seven minutes. A precise, digital prophecy of death.
"Is there anything you can do to prevent it?" he asked.
"We have administered the standard interventions. Anticoagulants, beta-blockers. But the system's predictions are remarkably accurate. If it says a cardiac event is imminent, it usually is."
The word *usually* echoed in Silas's mind. He looked at the old woman's face, peaceful in sleep, and then at the terminal, which displayed not just the alert but a stream of real-time biometric data. Heart rate: 72. Blood pressure: 138/82. Oxygen saturation: 96%. All within normal ranges for a woman of her age and condition.
"What is the basis for the high-risk prediction?" he asked.
"That information is proprietary," Dr. Cordova said. "OmniCure's algorithm is a trade secret. Even I don't know the specific variables it weighs. I only see the output."
Silas felt a chill that had nothing to do with the room temperature. A machine that could predict death but could not explain its reasoning. A machine whose judgments were unchallengeable because they were invisible.
"I'm going to stay here," he said. "Until the prediction is resolved."
Dr. Cordova hesitated, as if weighing an objection, then nodded. "As you wish. The night nurse will check on her hourly. If the system is correct... well, you will be here to witness it."
She left. Silas pulled a chair beside the bed and sat down, watching the countdown timer decrement minute by minute. Outside the window, the parking lot lights flickered once, then steadied. The fluorescent hum continued at 60 hertz. Everything was orderly. Everything was normal.
He pulled out his notebook and wrote, in the margin of the page where he had diagrammed VitalSync's logic:
*Tonight, a machine has predicted a death.* *If the death occurs, was it a prediction or a sentence?* *And what if I am the only one who can tell the difference?*
The timer read 10 hours and 52 minutes. Silas settled into his chair, prepared to wait, unaware that in the motel three miles away, Lila Vance had just received a visitor: a man in a dark suit who introduced himself as a representative of Asterion Equity Partners and who politely suggested that she return to her retirement and forget she had ever heard the name OmniCure.
She declined.
The man left a business card and a warning. "The Company protects its investments, Agent Vance. You of all people should understand the cost of being on the wrong side of progress."
When he was gone, Lila called Silas's room. There was no answer. She tried his cell phone, a number he rarely used. No answer.
She drove back to Tranquil Gardens at 2:00 AM, her bad knee aching, her mind sharpening into the focused intensity that had once made her the most dangerous interrogator in the Bureau. She found the front doors locked. The receptionist was gone. The night shift nurse was making rounds on the second floor, and did not hear the buzzer.
Inside Room 309, the countdown timer read 8 hours and 14 minutes. Silas sat in his chair, watching the screen, waiting for a machine to decide whether a woman would live or die, and wondering, in the quiet hours before dawn, whether he had already become complicit simply by watching.
No comments yet. Be the first to comment!